Hatton M W, Berry L R
Biochem Cell Biol. 1987 Apr;65(4):271-9. doi: 10.1139/o87-035.
Samples of human apotransferrin (apo . HTr) were saturated with Fe(III) by two different techniques, a method employing excess trisodium citrate to chelate Fe(III) and a nonchelating approach which involves the ferroxidase activity of ceruloplasmin to convert Fe(II)----Fe(III). The samples were radiolabelled with either 55Fe or 3H. Using an initial molar Fe/apo . HTr ratio of 2.0-2.1, preparations of human transferrin with bound Fe (Fe . HTr) using the citrate method invariably contained 2.2-2.4 atoms Fe/molecule, whereas Fe . HTr (ceruloplasmin method) contained 2.0 atoms/molecule as shown by spectrophotometric and radioactivity measurements. Uptake of Fe from these Fe . HTr preparations by K-562 cells grown in a serum-free medium was marginally, but consistently, more rapid from 55Fe . HTr (citrate) than from 55Fe . HTr (ceruloplasmin). Taking account of the different Fe contents of the Fe . HTr preparations, the rate measured over a 2-h period amounted to approximately 12,700 and 16,100 Fe atoms/(cell . min) for Fe . HTr (ceruloplasmin) and Fe . HTr (citrate), respectively. However, cell binding by the two Fe . [3H]HTr preparations did not differ significantly over the 8-h incubation period. Furthermore, from the 3H distribution, the quantities of Fe . HTr bound reversibly at the cell surface and contained within the cell were similar for the two Fe . HTr preparations. The results indicate that apo . HTr may bind Fe in different ways depending on the method of Fe presentation and that the Fe . HTr product can donate Fe to K-562 cells at a rate which may reflect the method used for Fe-complex formation.
人脱铁转铁蛋白(apo.HTr)样本通过两种不同技术用Fe(III)进行饱和处理,一种方法是使用过量柠檬酸钠螯合Fe(III),另一种非螯合方法是利用铜蓝蛋白的亚铁氧化酶活性将Fe(II)转化为Fe(III)。样本用55Fe或3H进行放射性标记。使用初始Fe/apo.HTr摩尔比为2.0 - 2.1,采用柠檬酸盐法制备的结合铁的人转铁蛋白(Fe.HTr)制剂每分子总是含有2.2 - 2.4个铁原子,而通过分光光度法和放射性测量显示,Fe.HTr(铜蓝蛋白法)每分子含有2.0个铁原子。在无血清培养基中生长的K - 562细胞从这些Fe.HTr制剂中摄取铁时,55Fe.HTr(柠檬酸盐法)比55Fe.HTr(铜蓝蛋白法)的摄取速度略快,但持续更快。考虑到Fe.HTr制剂中铁含量不同,在2小时内测量的摄取速率分别约为Fe.HTr(铜蓝蛋白法)12,700个铁原子/(细胞·分钟)和Fe.HTr(柠檬酸盐法)16,100个铁原子/(细胞·分钟)。然而,在8小时孵育期内,两种Fe.[3H]HTr制剂与细胞的结合没有显著差异。此外,从3H分布来看,两种Fe.HTr制剂在细胞表面可逆结合和细胞内所含的Fe.HTr量相似。结果表明,apo.HTr可能根据铁呈现的方法以不同方式结合铁,并且Fe.HTr产物可以以可能反映用于形成铁复合物的方法的速率将铁捐赠给K - 562细胞。